Poster Session D - Tuesday Morning
Sriya Muralidharan, MD
Duke University
Durham, NC
Phase 1 | Phase 2 | P1 vs. P2 | ||||
(N=46) 95% CI | (N=25) 95% CI | p-value | ||||
Raw Sample Presence ( >100 CFU) | ||||||
Site 1 | 0 (0%) | 0 (0%) | -- | |||
(0%, 7.7%) | (0%, 13.7%) | |||||
Site 2 | 0 (0%) | 1 (4.0%) | 0.35 | |||
(0%, 7.7%) | (0.1%, 20.4%) | |||||
Site 3 | 1 (2.2%) | 1 (4.0%) | 0.58 | |||
(0.1%, 11.5%) | (0.1%, 20.4%) | |||||
Site 4 | 7 (15.2%) | 0 (0%) | 1.00 | |||
(6.3%, 28.9%) | (0%, 13.7%) | |||||
Raw Sample Enterococcus Presence ( >1 CFU) | ||||||
Site 1 | 2 (4.3%) | 1 (4.0%) | 0.734 | |||
(0.5%, 14.8%) | (0.1%, 20.4%) | |||||
Site 2 | 2 (4.3%) | 2 (8.0%) | 0.441 | |||
(0.5%, 14.8%) | (1.0%, 26.0%) | |||||
Site 3 | 2 (4.3%) | 2 (8.0%) | 0.441 | |||
(0.5%, 14.8%) | (1.0%, 26.0%) | |||||
Site 4 | 0 (0%) | 0 (0%) | -- | |||
(0%, 7.7%) | (0%, 13.7%) | |||||
Raw Sample C. difficile Presence ( >1 CFU) | ||||||
Site 1 | 0 (0%) | 0 (0%) | -- | |||
(0%, 7.7%) | (0%, 13.7%) | |||||
Site 2 | 0 (0%) | 0 (0%) | -- | |||
(0%, 7.7%) | (0%, 13.7%) | |||||
Site 3 | 0 (0%) | 0 (0%) | -- | |||
(0%, 7.7%) | (0%, 13.7%) | |||||
Site 4 | 0 (0%) | 0 (0%) | -- | |||
(0%, 7.7%) | (0%, 13.7%) |